RxDoctor Payments Data

Julian Nunez, MD

Cardiovascular Disease · Saint Joseph, MONPI 1528054996

Payments from drug & device makers

$4,322in general payments, 2019–2025

Across 234 payments — averaging $18.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$744
  • Novartis$471
  • Medtronic$402
  • Amgen$394
  • E.r. Squibb & Sons, L.L.C.$294
  • Johnson & Johnson$237
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$4,17096%
  • Education$1524%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,322 in reported general payments places this provider in the 60th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$190,011
Medicare patients
2,869
Services billed
5,530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan85$115,411
EliquisApixaban66$90,186
XareltoRivaroxaban58$57,503
JardianceEmpagliflozin22$29,313
Repatha SureclickEvolocumab17$22,360
Metoprolol Succinate310$3,329
Ranolazine ErRanolazine29$3,038
Rosuvastatin Calcium240$2,828
Atorvastatin Calcium293$2,536
Carvedilol299$2,395
Prasugrel Hcl35$2,360
ClopidogrelClopidogrel Bisulfate171$1,771
Metoprolol Tartrate276$1,512
Diltiazem 24hr Er (Cd)Diltiazem Hcl54$1,497
Isosorbide Mononitrate ErIsosorbide Mononitrate137$1,477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$471$115,41185 claims
PfizerEliquis$205$90,18666 claims
Johnson & JohnsonXarelto$237$57,50358 claims
Boehringer IngelheimJardiance$81$29,31322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Saint Joseph

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →